How would you approach a metastatic ERBB2 amplified gallbladder carcinoma?
Would you consider adding trastuzumab to cis/gem in the first line? If not, would you consider adding Her2 directed therapy to FOLFIRI or FOLFOX in the second line? Or would you go to Pertuzumab/trastuzumab combination given MyPathway data. This in the setting of a patient who is not a trial candidate.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Jefferson Kimmel Cancer Center
Answered on
You have hit on a clinical scenario for which we have clues about helpful therapy, but no definitive data to guide us.
For a HER-2 amplified gallbladder or biliary cancer, I do think the data support targeting this pathway at some point in the patient’s care. As you point out, the best data are from...
Join for free or sign in to see the full answer